We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-41%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$147M
AUM Growth
-$523M
Cap. Flow
-$201M
Cap. Flow %
-136.49%
Top 10 Hldgs %
64.77%
Holding
167
New
23
Increased
38
Reduced
54
Closed
36

Top Buys

Rank Stock Value
1
GEVO icon
Gevo
GEVO
+$20.1M
2
DOGZ icon
Dogness International Corp
DOGZ
+$8.37M
3
ONCO icon
Onconetix
ONCO
+$5.5M
4
MMAT
Meta Materials Inc. Common Stock
MMAT
+$3.83M
5
NEPT
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
+$3.81M

Top Sells

Rank Stock Value
1
CNTX icon
Context Therapeutics
CNTX
+$2.53M
2
HMCO
HumanCo Acquisition Corp. Class A Common Stock
HMCO
+$1.42M
3
USWS
U.S. Well Services, Inc. Class A Common Stock
USWS
+$1.07M
4
GYRE icon
Gyre Therapeutics
GYRE
+$871K
5
AGMH icon
AGM Group Holdings
AGMH
+$859K

Sector Composition

Rank Sector Weight
1 Healthcare 12.65%
2 Materials 8.79%
3 Technology 5.39%
4 Consumer Discretionary 3.75%
5 Consumer Staples 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BETS
151
DELISTED
Bit Brother Limited Class A Ordinary Shares
BETS
– –
-33
Closed -$170K
SMFL
152
DELISTED
Smart for Life, Inc. Common Stock
SMFL
– –
-105
Closed -$369K
NMTR
153
PUT
DELISTED
9 Meters Biopharma
NMTR
– –
-6
Closed -$50K
KRBP
154
DELISTED
Kiromic BioPharma, Inc. Common Stock
KRBP
– –
-3,559
Closed -$91K
CYRN
155
DELISTED
CYREN Ltd.
CYRN
– –
-57,493
Closed -$290K
STAB
156
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
– –
-69,103
Closed -$22K
BIOR
157
CALL
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
– –
-8
Closed -$235K
AGTC
158
PUT
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-2,737
Closed -$293K
USWS
159
DELISTED
U.S. Well Services, Inc. Class A Common Stock
USWS
– –
-162,379
Closed -$1.07M
ATHX
160
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-11,658
Closed -$816K
ATHX
161
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-12
Closed -$86K
XELA
162
DELISTED
Exela Technologies, Inc. Common Stock
XELA
– –
-18
Closed -$29K
XELA
163
PUT
DELISTED
Exela Technologies, Inc. Common Stock
XELA
– –
0
– -$38K
SRGA
164
PUT
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-4
Closed -$4K
CFRX
165
DELISTED
ContraFect Corporation
CFRX
– –
-1,175
Closed -$332K
IO
166
PUT
DELISTED
ION Geophysical Corporation
IO
– –
-3,059
Closed -$267K
3 4 5 6
7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2022 Portfolio in Review

As of Q2 2022, Sabby Management held 167 positions worth $147M, down 78% from $670M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sabby Management withdrew a net $201M in Q2 2022, closing 36 positions and reducing 54 holdings. Its most notable exit was Context Therapeutics, an estimated $2.53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 7.6% a quarter earlier, followed by Materials and Technology.

Against the trend, Sabby Management opened a new position in Gevo worth $12.9M.

  • Sabby Management's largest Q2 2022 buy was Gevo: 5,486,831 shares worth $12.9M.
  • Sabby Management added most to Canaan Creative in Q2 2022, an estimated $1.46M increase.
  • Sabby Management's biggest Q2 2022 reduction was HumanCo Acquisition Corp. Class A Common Stock, cutting an estimated $1.42M.
  • Sabby Management fully exited Context Therapeutics in Q2 2022, selling an estimated $2.53M.
  • Sabby Management's ten largest holdings make up 65% of its $147M portfolio in Q2 2022.
  • Sabby Management opened 23 new positions and closed 36 in Q2 2022.
  • Sabby Management's portfolio value fell 78% quarter-over-quarter to $147M.

Based on Sabby Management's 13F filing for Q2 2022, filed 15 Aug 2022.